As the first wave of survivors of severe COVID-19 begin to leave hospitals, many face a new challenge—dialysis.

Many professional societies staked out the early position that COVID-19 patients should continue their blood pressure medications in the absence of a clear reason to stop them. And the early evidence to date has reinforced those recommendations.

As New York City hospitals braced for a potentially overwhelming surge of COVID-19 cases, Columbia University Medical Center nephrologist Sumit Mohan, MD, MPH, and his colleagues had to transform the way they provided kidney transplant care.

As COVID-19 started to take hold in countries like China and Italy, Marian Michaels, MD, MPH, thought the transplant community in the United States and Canada would benefit from having information about the then-rising epidemic so they could establish solid plans for their patients and programs. She had no idea how prescient that decision would be.

Like every corner of the medical community, kidney patient advocacy groups have mobilized in response to the COVID-19 pandemic. The many responses include direct monetary grants to patients; education for patients about the virus and how they can react; increased efforts for communication, networking, and counseling; and mobilization for political activity.

The world is struggling with the new and uncertain realities of the COVID-19 pandemic, which has challenged all facets of the healthcare system in unprecedented ways. As the initial experience in the United States has taught us, none are more vulnerable to COVID-19–related morbidity and mortality than the ESRD population (1).